Federica Piani1, Trenton Reinicke1, Yuliya Lytvyn2, Isabella Melena1, Leif E Lovblom3, Vesta Lai2, Josephine Tse2, Leslie Cham2, Andrej Orszag3, Bruce A Perkins4, David Z I Cherney5, Petter Bjornstad6. 1. Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, CO, USA; Department of Pediatrics, Section of Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA. 2. Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 3. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. 4. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 5. Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Physiology, University of Toronto, Canada. 6. Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, CO, USA; Department of Pediatrics, Section of Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: petter.m.bjornstad@cuanschutz.edu.
Abstract
OBJECTIVE: Arginine vasopressin (AVP) and its surrogate, copeptin, have been implicated in diabetic kidney disease (DKD) pathogenesis, which develops in a subset of people with longstanding type 1 diabetes, but not in others (DKD Resistors). We hypothesized that patients with DKD would exhibit higher copeptin concentrations vs. DKD Resistors. METHODS: Participants with type 1 diabetes (n = 62, duration ≥50 years) were stratified into 42 DKD Resistors and 20 with DKD (eGFR ≤60 mL/min/1.73m2 or ≥30 mg/day urine albumin), and age/sex-matched controls (HC, n = 74) were included. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were calculated by inulin and p-aminohippurate clearance before and after angiotensin II (ang II) infusion. Renal vascular resistance (RVR) was calculated as mean arterial pressure/renal blood flow. Plasma copeptin, renin, aldosterone, neutrophil gelatinase-associated lipocalin (NGAL), and urea concentrations were measured, along with 24-h urine volume. RESULTS: DKD resistors had lower copeptin (95% CI: 4.0 [3.4-4.8] pmol/l) compared to DKD (5.8 [4.5-7.6] pmol/l, p = 0.02) and HC (4.8 [4.1-5.5] pmol/l, p = 0.01) adjusting for age, sex and HbA1c. In type 1 diabetes, higher copeptin correlated with lower GFR (r: -0.32, p = 0.01) and higher renin concentration (r: 0.40, p = 0.002) after multivariable adjustments. These relationships were not evident in HC. Copeptin inversely associated with RVR change following exogenous ang II only in participants with type 1 diabetes (β ± SE: -6.9 ± 3.4, p = 0.04). CONCLUSIONS: In longstanding type 1 diabetes, copeptin was associated with intrarenal renin-angiotensin-aldosterone system (RAAS) activation and renal hemodynamic function, suggesting interplay between AVP and RAAS in DKD pathogenesis.
OBJECTIVE: Arginine vasopressin (AVP) and its surrogate, copeptin, have been implicated in diabetic kidney disease (DKD) pathogenesis, which develops in a subset of people with longstanding type 1 diabetes, but not in others (DKD Resistors). We hypothesized that patients with DKD would exhibit higher copeptin concentrations vs. DKD Resistors. METHODS: Participants with type 1 diabetes (n = 62, duration ≥50 years) were stratified into 42 DKD Resistors and 20 with DKD (eGFR ≤60 mL/min/1.73m2 or ≥30 mg/day urine albumin), and age/sex-matched controls (HC, n = 74) were included. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were calculated by inulin and p-aminohippurate clearance before and after angiotensin II (ang II) infusion. Renal vascular resistance (RVR) was calculated as mean arterial pressure/renal blood flow. Plasma copeptin, renin, aldosterone, neutrophil gelatinase-associated lipocalin (NGAL), and urea concentrations were measured, along with 24-h urine volume. RESULTS: DKD resistors had lower copeptin (95% CI: 4.0 [3.4-4.8] pmol/l) compared to DKD (5.8 [4.5-7.6] pmol/l, p = 0.02) and HC (4.8 [4.1-5.5] pmol/l, p = 0.01) adjusting for age, sex and HbA1c. In type 1 diabetes, higher copeptin correlated with lower GFR (r: -0.32, p = 0.01) and higher renin concentration (r: 0.40, p = 0.002) after multivariable adjustments. These relationships were not evident in HC. Copeptin inversely associated with RVR change following exogenous ang II only in participants with type 1 diabetes (β ± SE: -6.9 ± 3.4, p = 0.04). CONCLUSIONS: In longstanding type 1 diabetes, copeptin was associated with intrarenal renin-angiotensin-aldosterone system (RAAS) activation and renal hemodynamic function, suggesting interplay between AVP and RAAS in DKD pathogenesis.
Authors: Petter Bjornstad; Julie A Lovshin; Yuliya Lytvyn; Genevieve Boulet; Leif E Lovblom; Omar N Alhuzaim; Mohammed A Farooqi; Vesta Lai; Josephine Tse; Leslie Cham; Andrej Orszag; Daniel Scarr; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; Bruce A Perkins; David Z I Cherney Journal: Diabetes Care Date: 2018-02-02 Impact factor: 19.112
Authors: Petter Bjornstad; Sunita K Singh; Janet K Snell-Bergeon; Julie A Lovshin; Yuliya Lytvyn; Leif E Lovblom; Marian J Rewers; Genevieve Boulet; Vesta Lai; Josephine Tse; Leslie Cham; Andrej Orszag; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; Bruce A Perkins; David Z I Cherney Journal: Diabetes Obes Metab Date: 2018-11-11 Impact factor: 6.577
Authors: Wendy E Boertien; Esther Meijer; Paul E de Jong; Stephan J L Bakker; Frank S Czerwiec; Joachim Struck; Dorothee Oberdhan; Susan E Shoaf; Holly B Krasa; Ron T Gansevoort Journal: Kidney Int Date: 2013-07-31 Impact factor: 10.612
Authors: Etienne B Sochett; David Z I Cherney; Jacqueline R Curtis; Maria G Dekker; James W Scholey; Judith A Miller Journal: J Am Soc Nephrol Date: 2006-05-03 Impact factor: 10.121
Authors: Petter Bjornstad; David M Maahs; Thomas Jensen; Miguel A Lanaspa; Richard J Johnson; Marian Rewers; Janet K Snell-Bergeon Journal: J Diabetes Complications Date: 2016-04-19 Impact factor: 2.852
Authors: Melissa J Johnson; Kalie L Tommerdahl; Carissa Vinovskis; Sushrut Waikar; Trenton Reinicke; Chirag R Parikh; Wassim Obeid; Robert G Nelson; Daniel H van Raalte; Laura Pyle; Kristen J Nadeau; Petter Bjornstad Journal: Pediatr Nephrol Date: 2022-03-14 Impact factor: 3.651